Jeremy Goettel

Our lab is interested in understanding the mechanisms regulating intestinal immunity and what leads to dysregulation and disease as well as how gut microbes shape the mucosal immune system. In particular the cytokine interleukin-23 (IL23) is required for the development of many experimental models of inflammatory bowel disease (IBD) in mice and mutations in IL23 receptor (IL23R) have been identified as susceptibility or resistance factors for Crohn’s disease. We have developed several murine strains that will facilitate investigations into the role of IL23R signaling in a cell-specific manner using experimental models of IBD and inflammation-associated carcinogenesis. In addition, we have developed several humanized murine systems to model intestinal inflammation driven by human immune cells and new models enabling engraftment of human tumors with autologous immune cells to assess combination therapies and immune activation. We hope that these strategies will be informative for clinical management and pave the way towards precision medicine.

Companies

• Assistant Professor Vanderbilt University Medical Center (2017)
• Founder and CEO Transmedixen (2017)
• Instructor in Pediatrics Harvard Medical School (2015)
• Assistant Professor Harvard Medical School (2017 — 2017)
• Post-Doctoral Research Fellow Boston Children's Hospital (2011 — 2015)
• Post-Doctoral Research Fellow Massachusetts General Hospital (2010 — 2011)

Education

• Doctor of Philosophy (Ph.D.) Vanderbilt University (2003 — 2010)
• Bachelor's degree Missouri State University (1994 — 1998)